Targeting both RNA and the proteins that interact with it has become one of the hottest new areas in drug discovery. Biotechs such as Storm Therapeutics, 28-7, Gotham Therapeutics and Accent Therapeutics amongst many others, are all developing small molecule inhibitors of misregulated epigenetic processes.
On Wednesday, June 30th ZoBio organized together with Cambridge Healthtech Institute the webinar: “Epitranscriptomics and Disease: The Role of RNA Modification in the Life Cycle of the Cell”. During the webinar two of the top experts in the field: Samie R. Jaffrey, the Greenberg-Starr Professor in the Department of Pharmacology at the Weill Cornell Medical College and Sebastian Leidel, Professor in the Department of Chemistry, Biochemistry and Pharmaceutical Sciences (DCBP) University of Bern highlighted an exciting developments on RNA modifications and epitranscriptomics.
Both key opinion leaders shared their insights into the mechanisms of epitranscriptomics and its relationship to disease, in particular oncology. They described their latest findings on important targets and the biological outcome of inhibiting them. In addition, ZoBio shared a case study on development of small molecule inhibitors of an epitranscriptomic target.